See today's BioWorld AsiaSee today's BioWorld
To read the full story, subscribe or sign in.

FDA approves Daiichi Sankyo/Astrazeneca’s Enhertu for HER2 low metastatic breast cancer

Aug. 9, 2022
By Tamra Sami
The U.S. FDA has approved Daiichi Sankyo Co. Ltd. and Astrazeneca plc’s Enhertu (fam-trastuzumab deruxtecan) as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer.
BioWorld BioWorld Asia Regulatory Cancer Japan FDA